Sal La Rosa
About Sal La Rosa
Sal La Rosa is a seasoned financial executive currently serving as CFO at Avaamo and Principal at Perigee Advisors, LLC. He has extensive experience in finance management across various technology companies and holds an MBA from UCLA Anderson School of Management.
Current Role at Avaamo
Sal La Rosa serves as the Chief Financial Officer (CFO) at Avaamo, a position he has held since 2016. In this role, he is responsible for overseeing the financial operations of the company, contributing to its strategic direction and financial planning. His extensive experience in finance and management supports Avaamo's growth and operational efficiency.
Experience at Perigee Advisors, LLC
Since 2015, Sal La Rosa has been the Principal at Perigee Advisors, LLC, where he provides financial expertise with a focus on Financial Planning & Analysis and Operations. He launched this advisory firm to assist businesses in navigating financial challenges and optimizing their financial strategies.
Previous Positions in Finance
Prior to his current roles, Sal La Rosa held several significant positions in finance. He worked as a Business Unit Controller at McDATA from 2001 to 2004, and as a Finance Manager at Autodesk from 1998 to 1999. He also served as Director of FP&A at MediaLive International and as VP of Finance at TIBCO Software from 2006 to 2015, where he led a global team during a period of substantial revenue growth.
Educational Background
Sal La Rosa earned his MBA in Finance from the UCLA Anderson School of Management, studying from 1989 to 1991. He also holds a Bachelor of Science in Engineering from the University of Texas at Austin. His educational background provides a strong foundation for his career in finance and management.
Advisory Roles and Contributions
In addition to his corporate roles, Sal La Rosa has advised various companies in securing financing and preparing for growth. He has supported a privately-held SaaS events management platform in securing venture financing and assisted a VC-backed biotech company in preparing for an IPO by developing a long-range planning model.